Biocatalytic Production of a Key Chiral Intermediate of the HIV Capsid Inhibitor Lenacapavir

Authors:
Publisher website
Google Scholar
Abstract
Lenacapavir is a first-in-class viral capsid inhibitor approved for the treatment of HIV, which has been shown to give almost complete protection against transmission of the virus. However, the high costs currently associated with the manufacture of lenacapavir place restrictions on its wider application, making the development of cheaper synthetic routes a key priority. Herein we report the development of an engineered aminotransferase (ATA) for the asymmetric synthesis of the central chiral amine core of lenacapavir. Due to the sterically demanding nature of the ketone substrate, a substrate walking approach was adopted during directed evolution to unlock desired ATA activity starting from a parent template with no observable activity for the target reaction. Introduction of 10 mutations into an ATA from Ruegeria sp. TM1040 led to the development of a robust engineered ATA that allowed production of the target chiral amine product with high conversions (>98%), isolated yields (>90%), and optical purity (>99% ee). This engineered enzyme will facilitate the development of a biocatalytic process for a key chiral intermediate of lenacapavir in order to reduce its manufacturing costs and thereby enable global access to this important therapy.
Funding Information
  • Tianjin Institute of Industrial Biotechnology Chinese Academy of Sciences (TIB-CAS)
  • Henry Royce Institute (EP/P025021/1)
  • Henry Royce Institute (EP/P025498/1)
  • Henry Royce Institute (EP/R00661X/1)
  • Henry Royce Institute (EP/S019367/1)
  • Development of a national facility and technical training hub for ?Biomolecule Engineering? (UKRI055)
  • Future Biomanufacturing Hub (EP/S01778X/1)
  • National Natural Science Foundation of China (32401273)
  • Manchester SYNBIOCHEM Centre (BB/M017702/1)
  • Gates Foundation

This publication has 31 references indexed in Scilit: